Screener
Enliven Therapeutics ELVN Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $132,184 | $98,896 |
| Marketable securities | 320,217 | 363,725 |
| Prepaid expenses and other current assets | 10,736 | 12,257 |
| Total current assets | 463,137 | 474,878 |
| Property and equipment, net | 20 | 34 |
| Operating lease right-of-use assets | 290 | 383 |
| Deferred offering costs | 217 | 217 |
| Other long-term assets | 1,188 | 656 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's total current assets?
- Enliven Therapeutics (ELVN) reported total current assets of $463.14M in Q1 2026.
- How has Enliven Therapeutics's total current assets changed year-over-year?
- Enliven Therapeutics's total current assets increased by 57.4% year-over-year, from $294.32M to $463.14M.
- What is the long-term trend for Enliven Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Enliven Therapeutics's total current assets has grown at a 39.3% compound annual growth rate (CAGR), from $90.41M to $474.88M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Enliven Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude